

**Celentyx Ltd News Release
10th December 2008**



Celentyx announces continued collaboration with AMRI

Celentyx Ltd, a leader in the field of Neuroimmunopharmacology, announced today that AMRI has signed an agreement to further utilise Celentyx's technology to support the company's 5-HT₃ modulator program directed toward the treatment of irritable bowel syndrome.

"We are delighted to have the opportunity to continue working with AMRI," said Nicholas Barnes, CEO of Celentyx. "We have now worked together for over a year and it is very pleasing to see the evolution in the projects".

"We are delighted to continue to tap into Celentyx's expertise and technological processes. Our collaboration over the last year has proved to be very fruitful. The Celentyx team has made a key contribution toward demonstrating AMRI's innovative approach to this program," said Dr. David Manning, a senior research scientist and project leader for the 5-HT₃ program at AMRI.

###

Further information and high resolution images:

Dr Catherine Brady, Celentyx Ltd
Tel: +44 (0)121 414 8199 / Mobile: +44 (0)7725 963391
Email: catherine.brady@celentyx.com

NOTES TO EDITORS

Celentyx

Celentyx Ltd is an R&D-based company with a focus on human immune disease. Dysfunction of the immune system underlies numerous diseases including lymphoma, leukaemia, inflammation, allergy and autoimmune diseases. As key effectors within the immune system, lymphocytes are highly attractive targets for drug candidates in a wide variety of common life-debilitating or life-threatening diseases.

A spin-out from the University of Birmingham Medical School, Celentyx technology and expertise originated from the laboratories of Prof Nicholas Barnes and Prof John Gordon. Amongst the first in the world to recognise that many neurotransmitters also modify the immune system, Prof Barnes and Prof Gordon are internationally recognised authorities in this relatively new field of Neuroimmunopharmacology.

AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.